Perivascular Stem Cells: A Prospectively Purified Mesenchymal Stem Cell Population for Bone Tissue Engineering
Adipose tissue is an ideal source of mesenchymal stem cells for bone tissue engineering: it is largely dispensable and readily accessible with minimal morbidity. However, the stromal vascular fraction (SVF) of adipose tissue is a heterogeneous cell population, which leads to unreliable bone formatio...
Gespeichert in:
| Veröffentlicht in: | Stem cells translational medicine 2012-06, Vol.1 (6), p.510-519 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 519 |
|---|---|
| container_issue | 6 |
| container_start_page | 510 |
| container_title | Stem cells translational medicine |
| container_volume | 1 |
| creator | James, Aaron W. Zara, Janette N. Zhang, Xinli Askarinam, Asal Goyal, Raghav Chiang, Michael Yuan, Wei Chang, Le Corselli, Mirko Shen, Jia Pang, Shen Stoker, David Wu, Ben Ting, Kang Péault, Bruno Soo, Chia |
| description | Adipose tissue is an ideal source of mesenchymal stem cells for bone tissue engineering: it is largely dispensable and readily accessible with minimal morbidity. However, the stromal vascular fraction (SVF) of adipose tissue is a heterogeneous cell population, which leads to unreliable bone formation. In the present study, we prospectively purified human perivascular stem cells (PSCs) from adipose tissue and compared their bone‐forming capacity with that of traditionally derived SVF. PSCs are a population (sorted by fluorescence‐activated cell sorting) of pericytes (CD146+CD34−CD45−) and adventitial cells (CD146−CD34+CD45−), each of which we have previously reported to have properties of mesenchymal stem cells. Here, we found that PSCs underwent osteogenic differentiation in vitro and formed bone after intramuscular implantation without the need for predifferentiation. We next sought to optimize PSCs for in vivo bone formation, adopting a demineralized bone matrix for osteoinduction and tricalcium phosphate particle formulation for protein release. Patient‐matched, purified PSCs formed significantly more bone in comparison with traditionally derived SVF by all parameters. Recombinant bone morphogenetic protein 2 increased in vivo bone formation but with a massive adipogenic response. In contrast, recombinant Nel‐like molecule 1 (NELL‐1; a novel osteoinductive growth factor) selectively enhanced bone formation. These studies suggest that adipose‐derived human PSCs are a new cell source for future efforts in skeletal regenerative medicine. Moreover, PSCs are a stem cell‐based therapeutic that is readily approvable by the U.S. Food and Drug Administration, with potentially increased safety, purity, identity, potency, and efficacy. Finally, NELL‐1 is a candidate growth factor able to induce human PSC osteogenesis.
Adipose tissue is an ideal source of mesenchymal stem cells for bone tissue engineering, but the stromal vascular fraction (SVF) of adipose tissue is a heterogeneous cell population, which leads to unreliable bone formation. Human perivascular stem cells (PSCs) were prospectively purified from adipose tissue, and their bone‐forming capacity was compared with that of traditionally derived SVF. It was found that PSCs underwent osteogenic differentiation in vitro and formed bone after intramuscular implantation without the need for predifferentiation. These studies suggest that adipose‐derived human PSCs are a new cell source for future efforts in skele |
| doi_str_mv | 10.5966/sctm.2012-0002 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_24P</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3659717</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1221129355</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4680-2326598dbf8878d0f3d5f96d40815d2df2e37007b385f342557b81736779559f3</originalsourceid><addsrcrecordid>eNqFkUtvEzEUhS0EolXoliWyxIbNpH7ELxZIbVQoUhGRGtbWZOY6dTVjB3smKP8ej1LCY8PK1_J3z_W5B6HXlMyFkfIyN0M_Z4SyihDCnqFzRoWqpNDk-amWizN0kfNjIYg00jDyEp0xTo3SQpyjsILk93Vuxq5O-H6AHi-h6_J7fIVXKeYdNIPfQ3fAqzF556HFXyBDaB4Ofd39bsCruCsSg48Bu5jwdQyA1z7nEfBN2PoAZU7YvkIvXN1luHg6Z-jbx5v18ra6-_rp8_LqrmoWUpOKcSaF0e3Gaa10SxxvhTOyXRBNRctax4ArQtSGa-H4ggmhNpoqLpUyQhjHZ-jDUXc3bnpoGwhDqju7S76v08HG2tu_X4J_sNu4t7zMVUVpht49CaT4fYQ82N7nphitA8QxW8oYpcxwIQr69h_0MY4pFHuWMUM0F2wxUfMj1ZSt5gTu9BlK7JSmndK0U5p2SrM0vPnTwgn_lV0BzBH44Ts4_EfO3i_XfLpRKSjhPwGBEaxJ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2290835245</pqid></control><display><type>article</type><title>Perivascular Stem Cells: A Prospectively Purified Mesenchymal Stem Cell Population for Bone Tissue Engineering</title><source>Wiley Online Library Open Access</source><creator>James, Aaron W. ; Zara, Janette N. ; Zhang, Xinli ; Askarinam, Asal ; Goyal, Raghav ; Chiang, Michael ; Yuan, Wei ; Chang, Le ; Corselli, Mirko ; Shen, Jia ; Pang, Shen ; Stoker, David ; Wu, Ben ; Ting, Kang ; Péault, Bruno ; Soo, Chia</creator><creatorcontrib>James, Aaron W. ; Zara, Janette N. ; Zhang, Xinli ; Askarinam, Asal ; Goyal, Raghav ; Chiang, Michael ; Yuan, Wei ; Chang, Le ; Corselli, Mirko ; Shen, Jia ; Pang, Shen ; Stoker, David ; Wu, Ben ; Ting, Kang ; Péault, Bruno ; Soo, Chia</creatorcontrib><description>Adipose tissue is an ideal source of mesenchymal stem cells for bone tissue engineering: it is largely dispensable and readily accessible with minimal morbidity. However, the stromal vascular fraction (SVF) of adipose tissue is a heterogeneous cell population, which leads to unreliable bone formation. In the present study, we prospectively purified human perivascular stem cells (PSCs) from adipose tissue and compared their bone‐forming capacity with that of traditionally derived SVF. PSCs are a population (sorted by fluorescence‐activated cell sorting) of pericytes (CD146+CD34−CD45−) and adventitial cells (CD146−CD34+CD45−), each of which we have previously reported to have properties of mesenchymal stem cells. Here, we found that PSCs underwent osteogenic differentiation in vitro and formed bone after intramuscular implantation without the need for predifferentiation. We next sought to optimize PSCs for in vivo bone formation, adopting a demineralized bone matrix for osteoinduction and tricalcium phosphate particle formulation for protein release. Patient‐matched, purified PSCs formed significantly more bone in comparison with traditionally derived SVF by all parameters. Recombinant bone morphogenetic protein 2 increased in vivo bone formation but with a massive adipogenic response. In contrast, recombinant Nel‐like molecule 1 (NELL‐1; a novel osteoinductive growth factor) selectively enhanced bone formation. These studies suggest that adipose‐derived human PSCs are a new cell source for future efforts in skeletal regenerative medicine. Moreover, PSCs are a stem cell‐based therapeutic that is readily approvable by the U.S. Food and Drug Administration, with potentially increased safety, purity, identity, potency, and efficacy. Finally, NELL‐1 is a candidate growth factor able to induce human PSC osteogenesis.
Adipose tissue is an ideal source of mesenchymal stem cells for bone tissue engineering, but the stromal vascular fraction (SVF) of adipose tissue is a heterogeneous cell population, which leads to unreliable bone formation. Human perivascular stem cells (PSCs) were prospectively purified from adipose tissue, and their bone‐forming capacity was compared with that of traditionally derived SVF. It was found that PSCs underwent osteogenic differentiation in vitro and formed bone after intramuscular implantation without the need for predifferentiation. These studies suggest that adipose‐derived human PSCs are a new cell source for future efforts in skeletal regenerative medicine.</description><identifier>ISSN: 2157-6564</identifier><identifier>EISSN: 2157-6580</identifier><identifier>DOI: 10.5966/sctm.2012-0002</identifier><identifier>PMID: 23197855</identifier><language>eng</language><publisher>United States: AlphaMed Press</publisher><subject>Adipogenesis ; Adipose tissue ; Adipose Tissue, White - cytology ; Adipose Tissue, White - metabolism ; Administrative support ; Adult stem cells ; Animals ; Antigens, CD34 - metabolism ; Bone growth ; Bone marrow ; Bone matrix ; Bone Matrix - metabolism ; Bone morphogenetic protein 2 ; Bone Morphogenetic Protein 2 - metabolism ; Bone Morphogenetic Protein 2 - pharmacology ; Bone Regeneration ; Calcium phosphates ; Calcium Phosphates - metabolism ; CD146 Antigen - metabolism ; CD34 antigen ; CD45 antigen ; Cell Culture Techniques ; Data analysis ; Defects ; Experiments ; FDA approval ; Flow Cytometry ; Humans ; Immunohistochemistry ; Inventors ; Laboratories ; Leukocyte Common Antigens - metabolism ; Lipectomy ; Male ; Mesenchymal stem cells ; Mesenchymal Stromal Cells - cytology ; Mesenchymal Stromal Cells - drug effects ; Mesenchymal Stromal Cells - metabolism ; Mesenchyme ; Mice ; Mice, SCID ; Morbidity ; Nerve Tissue Proteins - metabolism ; Osteoblast ; Osteogenesis ; Pericytes ; Pericytes - cytology ; Pericytes - drug effects ; Population ; Prospective Studies ; Recombinant Proteins - metabolism ; Recombinant Proteins - pharmacology ; Regenerative medicine ; Regenerative Medicine - methods ; Scholarships & fellowships ; Stem cells ; Tissue engineering ; Tissue Engineering and Regenerative Medicine ; Tissue Scaffolds ; Tricalcium phosphate ; Writing ; X-Ray Microtomography</subject><ispartof>Stem cells translational medicine, 2012-06, Vol.1 (6), p.510-519</ispartof><rights>2012 AlphaMed Press</rights><rights>2012. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>AlphaMed Press 1066-5099/2012/$20.00/0 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4680-2326598dbf8878d0f3d5f96d40815d2df2e37007b385f342557b81736779559f3</citedby><cites>FETCH-LOGICAL-c4680-2326598dbf8878d0f3d5f96d40815d2df2e37007b385f342557b81736779559f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3659717/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3659717/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,724,777,781,861,882,1412,11543,27905,27906,45555,45556,46033,46457,53772,53774</link.rule.ids><linktorsrc>$$Uhttps://onlinelibrary.wiley.com/doi/abs/10.5966%2Fsctm.2012-0002$$EView_record_in_Wiley-Blackwell$$FView_record_in_$$GWiley-Blackwell</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23197855$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>James, Aaron W.</creatorcontrib><creatorcontrib>Zara, Janette N.</creatorcontrib><creatorcontrib>Zhang, Xinli</creatorcontrib><creatorcontrib>Askarinam, Asal</creatorcontrib><creatorcontrib>Goyal, Raghav</creatorcontrib><creatorcontrib>Chiang, Michael</creatorcontrib><creatorcontrib>Yuan, Wei</creatorcontrib><creatorcontrib>Chang, Le</creatorcontrib><creatorcontrib>Corselli, Mirko</creatorcontrib><creatorcontrib>Shen, Jia</creatorcontrib><creatorcontrib>Pang, Shen</creatorcontrib><creatorcontrib>Stoker, David</creatorcontrib><creatorcontrib>Wu, Ben</creatorcontrib><creatorcontrib>Ting, Kang</creatorcontrib><creatorcontrib>Péault, Bruno</creatorcontrib><creatorcontrib>Soo, Chia</creatorcontrib><title>Perivascular Stem Cells: A Prospectively Purified Mesenchymal Stem Cell Population for Bone Tissue Engineering</title><title>Stem cells translational medicine</title><addtitle>Stem Cells Transl Med</addtitle><description>Adipose tissue is an ideal source of mesenchymal stem cells for bone tissue engineering: it is largely dispensable and readily accessible with minimal morbidity. However, the stromal vascular fraction (SVF) of adipose tissue is a heterogeneous cell population, which leads to unreliable bone formation. In the present study, we prospectively purified human perivascular stem cells (PSCs) from adipose tissue and compared their bone‐forming capacity with that of traditionally derived SVF. PSCs are a population (sorted by fluorescence‐activated cell sorting) of pericytes (CD146+CD34−CD45−) and adventitial cells (CD146−CD34+CD45−), each of which we have previously reported to have properties of mesenchymal stem cells. Here, we found that PSCs underwent osteogenic differentiation in vitro and formed bone after intramuscular implantation without the need for predifferentiation. We next sought to optimize PSCs for in vivo bone formation, adopting a demineralized bone matrix for osteoinduction and tricalcium phosphate particle formulation for protein release. Patient‐matched, purified PSCs formed significantly more bone in comparison with traditionally derived SVF by all parameters. Recombinant bone morphogenetic protein 2 increased in vivo bone formation but with a massive adipogenic response. In contrast, recombinant Nel‐like molecule 1 (NELL‐1; a novel osteoinductive growth factor) selectively enhanced bone formation. These studies suggest that adipose‐derived human PSCs are a new cell source for future efforts in skeletal regenerative medicine. Moreover, PSCs are a stem cell‐based therapeutic that is readily approvable by the U.S. Food and Drug Administration, with potentially increased safety, purity, identity, potency, and efficacy. Finally, NELL‐1 is a candidate growth factor able to induce human PSC osteogenesis.
Adipose tissue is an ideal source of mesenchymal stem cells for bone tissue engineering, but the stromal vascular fraction (SVF) of adipose tissue is a heterogeneous cell population, which leads to unreliable bone formation. Human perivascular stem cells (PSCs) were prospectively purified from adipose tissue, and their bone‐forming capacity was compared with that of traditionally derived SVF. It was found that PSCs underwent osteogenic differentiation in vitro and formed bone after intramuscular implantation without the need for predifferentiation. These studies suggest that adipose‐derived human PSCs are a new cell source for future efforts in skeletal regenerative medicine.</description><subject>Adipogenesis</subject><subject>Adipose tissue</subject><subject>Adipose Tissue, White - cytology</subject><subject>Adipose Tissue, White - metabolism</subject><subject>Administrative support</subject><subject>Adult stem cells</subject><subject>Animals</subject><subject>Antigens, CD34 - metabolism</subject><subject>Bone growth</subject><subject>Bone marrow</subject><subject>Bone matrix</subject><subject>Bone Matrix - metabolism</subject><subject>Bone morphogenetic protein 2</subject><subject>Bone Morphogenetic Protein 2 - metabolism</subject><subject>Bone Morphogenetic Protein 2 - pharmacology</subject><subject>Bone Regeneration</subject><subject>Calcium phosphates</subject><subject>Calcium Phosphates - metabolism</subject><subject>CD146 Antigen - metabolism</subject><subject>CD34 antigen</subject><subject>CD45 antigen</subject><subject>Cell Culture Techniques</subject><subject>Data analysis</subject><subject>Defects</subject><subject>Experiments</subject><subject>FDA approval</subject><subject>Flow Cytometry</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Inventors</subject><subject>Laboratories</subject><subject>Leukocyte Common Antigens - metabolism</subject><subject>Lipectomy</subject><subject>Male</subject><subject>Mesenchymal stem cells</subject><subject>Mesenchymal Stromal Cells - cytology</subject><subject>Mesenchymal Stromal Cells - drug effects</subject><subject>Mesenchymal Stromal Cells - metabolism</subject><subject>Mesenchyme</subject><subject>Mice</subject><subject>Mice, SCID</subject><subject>Morbidity</subject><subject>Nerve Tissue Proteins - metabolism</subject><subject>Osteoblast</subject><subject>Osteogenesis</subject><subject>Pericytes</subject><subject>Pericytes - cytology</subject><subject>Pericytes - drug effects</subject><subject>Population</subject><subject>Prospective Studies</subject><subject>Recombinant Proteins - metabolism</subject><subject>Recombinant Proteins - pharmacology</subject><subject>Regenerative medicine</subject><subject>Regenerative Medicine - methods</subject><subject>Scholarships & fellowships</subject><subject>Stem cells</subject><subject>Tissue engineering</subject><subject>Tissue Engineering and Regenerative Medicine</subject><subject>Tissue Scaffolds</subject><subject>Tricalcium phosphate</subject><subject>Writing</subject><subject>X-Ray Microtomography</subject><issn>2157-6564</issn><issn>2157-6580</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFkUtvEzEUhS0EolXoliWyxIbNpH7ELxZIbVQoUhGRGtbWZOY6dTVjB3smKP8ej1LCY8PK1_J3z_W5B6HXlMyFkfIyN0M_Z4SyihDCnqFzRoWqpNDk-amWizN0kfNjIYg00jDyEp0xTo3SQpyjsILk93Vuxq5O-H6AHi-h6_J7fIVXKeYdNIPfQ3fAqzF556HFXyBDaB4Ofd39bsCruCsSg48Bu5jwdQyA1z7nEfBN2PoAZU7YvkIvXN1luHg6Z-jbx5v18ra6-_rp8_LqrmoWUpOKcSaF0e3Gaa10SxxvhTOyXRBNRctax4ArQtSGa-H4ggmhNpoqLpUyQhjHZ-jDUXc3bnpoGwhDqju7S76v08HG2tu_X4J_sNu4t7zMVUVpht49CaT4fYQ82N7nphitA8QxW8oYpcxwIQr69h_0MY4pFHuWMUM0F2wxUfMj1ZSt5gTu9BlK7JSmndK0U5p2SrM0vPnTwgn_lV0BzBH44Ts4_EfO3i_XfLpRKSjhPwGBEaxJ</recordid><startdate>201206</startdate><enddate>201206</enddate><creator>James, Aaron W.</creator><creator>Zara, Janette N.</creator><creator>Zhang, Xinli</creator><creator>Askarinam, Asal</creator><creator>Goyal, Raghav</creator><creator>Chiang, Michael</creator><creator>Yuan, Wei</creator><creator>Chang, Le</creator><creator>Corselli, Mirko</creator><creator>Shen, Jia</creator><creator>Pang, Shen</creator><creator>Stoker, David</creator><creator>Wu, Ben</creator><creator>Ting, Kang</creator><creator>Péault, Bruno</creator><creator>Soo, Chia</creator><general>AlphaMed Press</general><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201206</creationdate><title>Perivascular Stem Cells: A Prospectively Purified Mesenchymal Stem Cell Population for Bone Tissue Engineering</title><author>James, Aaron W. ; Zara, Janette N. ; Zhang, Xinli ; Askarinam, Asal ; Goyal, Raghav ; Chiang, Michael ; Yuan, Wei ; Chang, Le ; Corselli, Mirko ; Shen, Jia ; Pang, Shen ; Stoker, David ; Wu, Ben ; Ting, Kang ; Péault, Bruno ; Soo, Chia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4680-2326598dbf8878d0f3d5f96d40815d2df2e37007b385f342557b81736779559f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adipogenesis</topic><topic>Adipose tissue</topic><topic>Adipose Tissue, White - cytology</topic><topic>Adipose Tissue, White - metabolism</topic><topic>Administrative support</topic><topic>Adult stem cells</topic><topic>Animals</topic><topic>Antigens, CD34 - metabolism</topic><topic>Bone growth</topic><topic>Bone marrow</topic><topic>Bone matrix</topic><topic>Bone Matrix - metabolism</topic><topic>Bone morphogenetic protein 2</topic><topic>Bone Morphogenetic Protein 2 - metabolism</topic><topic>Bone Morphogenetic Protein 2 - pharmacology</topic><topic>Bone Regeneration</topic><topic>Calcium phosphates</topic><topic>Calcium Phosphates - metabolism</topic><topic>CD146 Antigen - metabolism</topic><topic>CD34 antigen</topic><topic>CD45 antigen</topic><topic>Cell Culture Techniques</topic><topic>Data analysis</topic><topic>Defects</topic><topic>Experiments</topic><topic>FDA approval</topic><topic>Flow Cytometry</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Inventors</topic><topic>Laboratories</topic><topic>Leukocyte Common Antigens - metabolism</topic><topic>Lipectomy</topic><topic>Male</topic><topic>Mesenchymal stem cells</topic><topic>Mesenchymal Stromal Cells - cytology</topic><topic>Mesenchymal Stromal Cells - drug effects</topic><topic>Mesenchymal Stromal Cells - metabolism</topic><topic>Mesenchyme</topic><topic>Mice</topic><topic>Mice, SCID</topic><topic>Morbidity</topic><topic>Nerve Tissue Proteins - metabolism</topic><topic>Osteoblast</topic><topic>Osteogenesis</topic><topic>Pericytes</topic><topic>Pericytes - cytology</topic><topic>Pericytes - drug effects</topic><topic>Population</topic><topic>Prospective Studies</topic><topic>Recombinant Proteins - metabolism</topic><topic>Recombinant Proteins - pharmacology</topic><topic>Regenerative medicine</topic><topic>Regenerative Medicine - methods</topic><topic>Scholarships & fellowships</topic><topic>Stem cells</topic><topic>Tissue engineering</topic><topic>Tissue Engineering and Regenerative Medicine</topic><topic>Tissue Scaffolds</topic><topic>Tricalcium phosphate</topic><topic>Writing</topic><topic>X-Ray Microtomography</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>James, Aaron W.</creatorcontrib><creatorcontrib>Zara, Janette N.</creatorcontrib><creatorcontrib>Zhang, Xinli</creatorcontrib><creatorcontrib>Askarinam, Asal</creatorcontrib><creatorcontrib>Goyal, Raghav</creatorcontrib><creatorcontrib>Chiang, Michael</creatorcontrib><creatorcontrib>Yuan, Wei</creatorcontrib><creatorcontrib>Chang, Le</creatorcontrib><creatorcontrib>Corselli, Mirko</creatorcontrib><creatorcontrib>Shen, Jia</creatorcontrib><creatorcontrib>Pang, Shen</creatorcontrib><creatorcontrib>Stoker, David</creatorcontrib><creatorcontrib>Wu, Ben</creatorcontrib><creatorcontrib>Ting, Kang</creatorcontrib><creatorcontrib>Péault, Bruno</creatorcontrib><creatorcontrib>Soo, Chia</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Stem cells translational medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>James, Aaron W.</au><au>Zara, Janette N.</au><au>Zhang, Xinli</au><au>Askarinam, Asal</au><au>Goyal, Raghav</au><au>Chiang, Michael</au><au>Yuan, Wei</au><au>Chang, Le</au><au>Corselli, Mirko</au><au>Shen, Jia</au><au>Pang, Shen</au><au>Stoker, David</au><au>Wu, Ben</au><au>Ting, Kang</au><au>Péault, Bruno</au><au>Soo, Chia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Perivascular Stem Cells: A Prospectively Purified Mesenchymal Stem Cell Population for Bone Tissue Engineering</atitle><jtitle>Stem cells translational medicine</jtitle><addtitle>Stem Cells Transl Med</addtitle><date>2012-06</date><risdate>2012</risdate><volume>1</volume><issue>6</issue><spage>510</spage><epage>519</epage><pages>510-519</pages><issn>2157-6564</issn><eissn>2157-6580</eissn><abstract>Adipose tissue is an ideal source of mesenchymal stem cells for bone tissue engineering: it is largely dispensable and readily accessible with minimal morbidity. However, the stromal vascular fraction (SVF) of adipose tissue is a heterogeneous cell population, which leads to unreliable bone formation. In the present study, we prospectively purified human perivascular stem cells (PSCs) from adipose tissue and compared their bone‐forming capacity with that of traditionally derived SVF. PSCs are a population (sorted by fluorescence‐activated cell sorting) of pericytes (CD146+CD34−CD45−) and adventitial cells (CD146−CD34+CD45−), each of which we have previously reported to have properties of mesenchymal stem cells. Here, we found that PSCs underwent osteogenic differentiation in vitro and formed bone after intramuscular implantation without the need for predifferentiation. We next sought to optimize PSCs for in vivo bone formation, adopting a demineralized bone matrix for osteoinduction and tricalcium phosphate particle formulation for protein release. Patient‐matched, purified PSCs formed significantly more bone in comparison with traditionally derived SVF by all parameters. Recombinant bone morphogenetic protein 2 increased in vivo bone formation but with a massive adipogenic response. In contrast, recombinant Nel‐like molecule 1 (NELL‐1; a novel osteoinductive growth factor) selectively enhanced bone formation. These studies suggest that adipose‐derived human PSCs are a new cell source for future efforts in skeletal regenerative medicine. Moreover, PSCs are a stem cell‐based therapeutic that is readily approvable by the U.S. Food and Drug Administration, with potentially increased safety, purity, identity, potency, and efficacy. Finally, NELL‐1 is a candidate growth factor able to induce human PSC osteogenesis.
Adipose tissue is an ideal source of mesenchymal stem cells for bone tissue engineering, but the stromal vascular fraction (SVF) of adipose tissue is a heterogeneous cell population, which leads to unreliable bone formation. Human perivascular stem cells (PSCs) were prospectively purified from adipose tissue, and their bone‐forming capacity was compared with that of traditionally derived SVF. It was found that PSCs underwent osteogenic differentiation in vitro and formed bone after intramuscular implantation without the need for predifferentiation. These studies suggest that adipose‐derived human PSCs are a new cell source for future efforts in skeletal regenerative medicine.</abstract><cop>United States</cop><pub>AlphaMed Press</pub><pmid>23197855</pmid><doi>10.5966/sctm.2012-0002</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | ISSN: 2157-6564 |
| ispartof | Stem cells translational medicine, 2012-06, Vol.1 (6), p.510-519 |
| issn | 2157-6564 2157-6580 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3659717 |
| source | Wiley Online Library Open Access |
| subjects | Adipogenesis Adipose tissue Adipose Tissue, White - cytology Adipose Tissue, White - metabolism Administrative support Adult stem cells Animals Antigens, CD34 - metabolism Bone growth Bone marrow Bone matrix Bone Matrix - metabolism Bone morphogenetic protein 2 Bone Morphogenetic Protein 2 - metabolism Bone Morphogenetic Protein 2 - pharmacology Bone Regeneration Calcium phosphates Calcium Phosphates - metabolism CD146 Antigen - metabolism CD34 antigen CD45 antigen Cell Culture Techniques Data analysis Defects Experiments FDA approval Flow Cytometry Humans Immunohistochemistry Inventors Laboratories Leukocyte Common Antigens - metabolism Lipectomy Male Mesenchymal stem cells Mesenchymal Stromal Cells - cytology Mesenchymal Stromal Cells - drug effects Mesenchymal Stromal Cells - metabolism Mesenchyme Mice Mice, SCID Morbidity Nerve Tissue Proteins - metabolism Osteoblast Osteogenesis Pericytes Pericytes - cytology Pericytes - drug effects Population Prospective Studies Recombinant Proteins - metabolism Recombinant Proteins - pharmacology Regenerative medicine Regenerative Medicine - methods Scholarships & fellowships Stem cells Tissue engineering Tissue Engineering and Regenerative Medicine Tissue Scaffolds Tricalcium phosphate Writing X-Ray Microtomography |
| title | Perivascular Stem Cells: A Prospectively Purified Mesenchymal Stem Cell Population for Bone Tissue Engineering |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T13%3A48%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_24P&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Perivascular%20Stem%20Cells:%20A%20Prospectively%20Purified%20Mesenchymal%20Stem%20Cell%20Population%20for%20Bone%20Tissue%20Engineering&rft.jtitle=Stem%20cells%20translational%20medicine&rft.au=James,%20Aaron%20W.&rft.date=2012-06&rft.volume=1&rft.issue=6&rft.spage=510&rft.epage=519&rft.pages=510-519&rft.issn=2157-6564&rft.eissn=2157-6580&rft_id=info:doi/10.5966/sctm.2012-0002&rft_dat=%3Cproquest_24P%3E1221129355%3C/proquest_24P%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2290835245&rft_id=info:pmid/23197855&rfr_iscdi=true |